The oral capsule Zeponim (Ozanimod), developed by experts at Alborz Zagros Pharmaceutical Company, a subsidiary of Actover Group, has been introduced to the Iranian pharmaceutical market for the management of relapsing forms of Multiple Sclerosis (MS) and Ulcerative Colitis (UC).

According to Actover Group’s Public Relations, the medicine will be available from early September in oral capsule forms of 0.23 mg, 0.46 mg, and 0.92 mg. Zeponim is indicated for the treatment of relapsing forms of MS in adults, including Clinically Isolated Syndrome (CIS), Relapsing-Remitting MS (RRMS), and active Secondary Progressive MS (SPMS). It is also prescribed for the treatment of moderately to severely active Ulcerative Colitis.

Ozanimod is an oral immunomodulator that acts as a selective sphingosine-1-phosphate (S1P) receptor modulator. By binding selectively to S1P receptors, it reduces the migration of lymphocytes into the central nervous system and inflamed tissues, helping to control inflammation and slow disease progression.

The launch ceremony for Zeponim was held on Friday, August 8, at Espinas Palace Hotel, attended by a large number of neurologists and specialists. Keynote speeches were delivered by Dr. Amir Reza Azimi, Dr. Mohammad Ali Sahraian, and Dr. Seyed Masoud Nabavi, renowned neurologists and MS fellows, who discussed the drug’s mechanism of action, clinical indications, results of clinical trials, practical experiences in MS treatment, and important considerations for patient monitoring.